Get started
ULTRAGENYX PHARMACEUTICAL INCULTRAGENYX PHARMACEUTICAL INCULTRAGENYX PHARMACEUTICAL INC

ULTRAGENYX PHARMACEUTICAL INC

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

UP0 chart


Full chart

UP0 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.14 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.44 EUR
Net income (FY)
‪−549.82 M‬ EUR
Revenue (FY)
‪541.17 M‬ EUR
Shares float
‪88.38 M‬
Beta (1Y)
1.04

Employees


Employees (FY)
‪1.29 K‬
Change (1Y)
+18 +1.41%
Revenue / Employee (1Y)
‪418.21 K‬ EUR
Net income / Employee (1Y)
‪−424.90 K‬ EUR

About Ultragenyx Pharmaceutical Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Emil D. Kakkis
Website
ultragenyx.com
Headquarters
Novato
Founded
2010
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Check out other big names from the same industry as UP0.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

UP0 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of UP0 is 22.60 EUR — it has decreased by −1.74% in the past 24 hours. Watch ULTRAGENYX PHARMACEUTICAL INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ULTRAGENYX PHARMACEUTICAL INC stocks are traded under the ticker UP0.
UP0 stock has fallen by −5.83% compared to the previous week, the month change is a −29.81% fall, over the last year ULTRAGENYX PHARMACEUTICAL INC has showed a −42.35% decrease.
We've gathered analysts' opinions on ULTRAGENYX PHARMACEUTICAL INC future price: according to them, UP0 price has a max estimate of 117.03 EUR and a min estimate of 29.26 EUR. Watch UP0 chart and read a more detailed ULTRAGENYX PHARMACEUTICAL INC stock forecast: see what analysts think of ULTRAGENYX PHARMACEUTICAL INC and suggest that you do with its stocks.
UP0 reached its all-time high on Sep 16, 2024 with the price of 54.00 EUR, and its all-time low was 23.00 EUR and was reached on Jul 15, 2025. View more price dynamics on UP0 chart.
See other stocks reaching their highest and lowest prices.
UP0 stock is 2.68% volatile and has beta coefficient of 1.04. Track ULTRAGENYX PHARMACEUTICAL INC stock price on the chart and check out the list of the most volatile stocks — is ULTRAGENYX PHARMACEUTICAL INC there?
Today ULTRAGENYX PHARMACEUTICAL INC has the market capitalization of ‪2.14 B‬, it has decreased by −6.39% over the last week.
Yes, you can track ULTRAGENYX PHARMACEUTICAL INC financials in yearly and quarterly reports right on TradingView.
ULTRAGENYX PHARMACEUTICAL INC is going to release the next earnings report on Jul 31, 2025. Keep track of upcoming events with our Earnings Calendar.
UP0 earnings for the last quarter are −1.45 EUR per share, whereas the estimation was −1.48 EUR resulting in a 1.74% surprise. The estimated earnings for the next quarter are −1.10 EUR per share. See more details about ULTRAGENYX PHARMACEUTICAL INC earnings.
ULTRAGENYX PHARMACEUTICAL INC revenue for the last quarter amounts to ‪128.75 M‬ EUR, despite the estimated figure of ‪132.94 M‬ EUR. In the next quarter, revenue is expected to reach ‪137.49 M‬ EUR.
UP0 net income for the last quarter is ‪−139.65 M‬ EUR, while the quarter before that showed ‪−128.85 M‬ EUR of net income which accounts for −8.38% change. Track more ULTRAGENYX PHARMACEUTICAL INC financial stats to get the full picture.
No, UP0 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 21, 2025, the company has ‪1.29 K‬ employees. See our rating of the largest employees — is ULTRAGENYX PHARMACEUTICAL INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ULTRAGENYX PHARMACEUTICAL INC EBITDA is ‪−441.72 M‬ EUR, and current EBITDA margin is −89.33%. See more stats in ULTRAGENYX PHARMACEUTICAL INC financial statements.
Like other stocks, UP0 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ULTRAGENYX PHARMACEUTICAL INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ULTRAGENYX PHARMACEUTICAL INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ULTRAGENYX PHARMACEUTICAL INC stock shows the strong sell signal. See more of ULTRAGENYX PHARMACEUTICAL INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.